Literature DB >> 11055826

Clinical and serological aspects of patients with anti-Jo-1 antibodies--an evolving spectrum of disease manifestations.

W A Schmidt1, W Wetzel, R Friedländer, R Lange, H F Sörensen, H J Lichey, E Genth, R Mierau, E Gromnica-Ihle.   

Abstract

The aim of this study was to compare ELISA, immunodiffusion and immunoblot for the detection of anti-Jo-1 antibodies, and to investigate the association of the results with clinical manifestations. In two medical centres for rheumatology and one for pulmonology, all patients with suspected connective tissue disease were screened over a 5-year period for anti-Jo-1 antibodies by ELISA. Positive sera were controlled in another laboratory by immunodiffusion. If immunodiffusion was negative, sera were controlled again by ELISA. ELISA-positive immunodiffusion-negative sera were tested by immunoblotting. The patients were characterised clinically, and their clinical signs and symptoms were compared with those of 257 patients with anti-Jo-1 antibodies published in 15 case series and 30 case reports. Twenty-five patients had a positive ELISA test. Fifteen sera were positive by ELISA and immunodiffusion (group 1). Three sera showed high titres in both ELISA tests with negative immunodiffusion and immunoblot (group 2). Seven sera showed low titres in both ELISA tests. The results were negative in the other tests (group 3). Patients in groups 1 and 2 could be classified as Jo-1 syndrome patients. Of these 18 patients, 15 had arthritis, 14 had myositis and 14 had interstitial lung disease. Only four patients had myositis at disease onset. We describe four unusual patients with Jo-1 syndrome in detail: 1. Long history of seronegative rheumatoid arthritis; 2. Sjögren's syndrome with Ro- and La-antibodies; 3. Scleroderma and bronchial carcinoma with centromere antibodies; 4. Corticoid-sensitive psychosis. Patients with suspected connective tissue disease may be screened for anti-Jo-1 antibodies by ELISA. It detects some patients that are missed by immunodiffusion. Especially lower ELISA titres should be controlled by another method because of the low specificity of the test. The clinical picture is variable. Most patients have features other than myositis at disease onset.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11055826     DOI: 10.1007/s100670070030

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  26 in total

1.  Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

Authors:  Lesley Ann Saketkoo; Dana P Ascherman; Vincent Cottin; Lisa Christopher-Stine; Sonye K Danoff; Chester V Oddis
Journal:  Curr Rheumatol Rev       Date:  2010-05

2.  Is polymyositis or dermatomyositis in patients with rheumatoid arthritis induced or unveiled by anti-tumor necrosis factor treatment?

Authors:  Takao Nagashima; Seiji Minota
Journal:  Clin Rheumatol       Date:  2010-04-20       Impact factor: 2.980

3.  Antisynthetase syndrome associated with long-standing rheumatoid arthritis.

Authors:  Takao Nagashima; Masahiro Iwamoto; Seiji Minota
Journal:  Rheumatol Int       Date:  2010-03-30       Impact factor: 2.631

4.  Interstitial lung disease in a patient with antisynthetase syndrome and no myositis.

Authors:  Sotiris C Plastiras; Fotini C Soliotis; Panayiotis Vlachoyiannopoulos; George E Tzelepis
Journal:  Clin Rheumatol       Date:  2005-11-23       Impact factor: 2.980

5.  Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease.

Authors:  Thomas J Richards; Aaron Eggebeen; Kevin Gibson; Samuel Yousem; Carl Fuhrman; Bernadette R Gochuico; Noreen Fertig; Chester V Oddis; Naftali Kaminski; Ivan O Rosas; Dana P Ascherman
Journal:  Arthritis Rheum       Date:  2009-07

Review 6.  Myositis-related interstitial lung disease and antisynthetase syndrome.

Authors:  Joshua Solomon; Jeffrey J Swigris; Kevin K Brown
Journal:  J Bras Pneumol       Date:  2011 Jan-Feb       Impact factor: 2.624

Review 7.  Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group.

Authors:  Lorenzo Cavagna; Laura Nuño; Carlo Alberto Scirè; Marcello Govoni; Francisco Javier Lopez Longo; Franco Franceschini; Rossella Neri; Santos Castañeda; Walter Alberto Sifuentes Giraldo; Roberto Caporali; Florenzo Iannone; Enrico Fusaro; Giuseppe Paolazzi; Raffaele Pellerito; Andreas Schwarting; Lesley Ann Saketkoo; Norberto Ortego-Centeno; Luca Quartuccio; Elena Bartoloni; Christof Specker; Trinitario Pina Murcia; Renato La Corte; Federica Furini; Valentina Foschi; Javier Bachiller Corral; Paolo Airò; Ilaria Cavazzana; Julia Martínez-Barrio; Michelle Hinojosa; Margherita Giannini; Simone Barsotti; Julia Menke; Kostantinos Triantafyllias; Rosetta Vitetta; Alessandra Russo; Laura Bogliolo; Gianluigi Bajocchi; Elena Bravi; Giovanni Barausse; Roberto Bortolotti; Carlo Selmi; Simone Parisi; Fausto Salaffi; Carlomaurizio Montecucco; Miguel Angel González-Gay
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 8.  Clinical heterogeneity and outcomes of antisynthetase syndrome.

Authors:  Baptiste Hervier; Olivier Benveniste
Journal:  Curr Rheumatol Rep       Date:  2013-08       Impact factor: 4.592

9.  Myopathy with antibodies to the signal recognition particle: clinical and pathological features.

Authors:  T Miller; M T Al-Lozi; G Lopate; A Pestronk
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-10       Impact factor: 10.154

10.  Autoantibodies and their significance in myositis.

Authors:  Ira N Targoff
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.